duchenn
muscular
dystrophi
dmd
x
chromosomelink
progress
fatal
degen
muscl
disord
affect
approxim
male
birth
worldwid
sign
diseas
visibl
earli
childhood
year
compris
delay
abil
walk
waddl
gait
impair
movement
difficulti
run
frequent
fall
progress
muscl
weak
joint
contractur
lead
loss
ambul
wheelchair
depend
around
age
scoliosi
frequent
complic
start
develop
soon
loss
autonom
ambul
occur
caus
signific
neg
impact
respiratori
system
restrict
diaphragmat
movement
pulmonari
expans
compromis
respiratori
function
around
age
mechan
ventil
may
necessari
sustain
life
myocardi
impair
origin
inferolater
wall
progress
lead
left
ventricular
fibrosi
dysfunct
cognit
impair
compon
dmd
deficit
short
term
memori
multitask
procedur
learn
problemsolv
attribut
dysfunct
cerebrocerebellar
pathway
recent
becom
topic
thorough
investig
affect
individu
succumb
due
repeat
pulmonari
infect
aris
mechan
support
andor
cardiac
muscl
impair
dmd
patient
reach
adolesc
improv
current
pharmaceut
regim
mean
mani
may
live
fourth
decad
howev
extens
life
expect
achiev
adequ
time
manag
cardiopulmonari
respiratori
complic
due
halt
natur
progress
diseas
therefor
expand
patient
popul
current
repres
challeng
medic
commun
patient
gradual
requir
elabor
multidisciplinari
approach
treatment
surveil
manag
plan
adher
intern
standard
care
care
implement
close
monitor
maxim
patient
qualiti
life
dmd
caus
mutat
largest
known
human
gene
call
dystrophin
dmd
span
kb
genom
dna
exon
dmd
encod
dystrophin
kda
protein
local
cytoplasm
side
sarcolemma
skelet
cardiac
muscl
fiber
well
corticalcerebellar
synaps
common
mutat
nonrandomli
distribut
delet
approxim
may
span
one
exon
surprisingli
extent
gene
delet
correl
onset
sever
clinic
manifest
exon
duplic
missens
frameshift
point
intron
mutat
account
rest
dmd
case
mutat
result
shift
open
read
frame
gener
prematur
termin
codon
lead
exclus
one
exon
aberr
mrna
transcript
undergo
nonsensemedi
decay
therefor
almost
dystrophin
produc
dystrophin
normal
function
anchor
actin
cytoskeleton
connect
tissu
via
sarcoplasm
complex
call
dystrophin
glycoprotein
complex
dgc
fig
muscl
fiber
lack
dystrophin
subject
increas
mechan
stress
suscept
damag
upon
contract
disrupt
sarcolemm
integr
caus
abnorm
influx
ion
cytosol
aberr
activ
calcium
bind
element
calciumdepend
proteas
proinflammatori
cytokin
effect
promot
skelet
muscl
regener
compensatori
action
counterbal
loss
function
alter
myogen
signal
caus
impair
prolif
capac
exhaust
satellit
cell
pool
replac
muscl
fibrot
tissu
eventu
result
necrosi
muscl
wast
effect
exacerb
function
ischemia
affect
muscl
due
detach
neuron
nitric
oxid
synthas
sarcolemma
normal
regul
vasoconstrict
muscl
exercis
less
sever
allyl
form
dmd
call
becker
muscular
dystrophi
gener
dystrophin
read
frame
maintain
approxim
case
gener
dystrophin
protein
product
shorter
less
abund
still
partial
function
becker
patient
dmd
mutat
consist
larg
delet
duplic
point
mutat
dystrophin
detect
rang
sever
case
even
mild
case
becker
patient
may
remain
ambulatori
past
year
age
milder
diseas
progress
attribut
exist
function
dystrophin
detect
muscl
fiber
notion
led
hypothesi
correct
read
frame
dmd
patient
success
would
lead
product
truncat
albeit
semifunct
dystrophin
transcript
code
protein
isoform
remain
resist
proteolyt
degrad
could
properli
local
sarcolemma
way
connect
extracellular
matrix
cytoskelet
muscl
fiber
costamer
could
restor
reestablish
link
contractil
apparatu
therefor
modif
dystrophin
premrna
process
result
product
intern
delet
protein
preserv
n
c
termin
domain
link
cytoskeleton
extracellular
matrix
respect
might
key
dmd
futur
gene
therapi
restor
disrupt
open
read
frame
dmd
transcript
gener
bmd
phenotyp
origin
attempt
vitro
target
exon
kobe
dmd
phenotyp
becom
basi
exon
skip
therapeut
approach
strategi
use
synthet
singlestrand
dnalik
molecul
call
antisens
oligonucleotid
aso
potenti
hybrid
rna
sequenc
motif
prevent
assembl
spliceosom
restor
translat
mrna
transcript
aso
commonli
design
bind
splice
junction
steric
block
access
splice
factor
target
site
alter
premrna
splice
aso
may
also
bind
exon
splice
enhanc
silenc
either
promot
block
splice
effect
unmodifi
aso
use
origin
subject
degrad
endonucleas
andor
exonucleas
therefor
therapeut
potenti
de
facto
limit
variou
chemic
modif
phosphoribos
backbon
perform
order
improv
stabil
efficaci
pharmacokinet
aso
substitut
nonbridg
phosphat
oxygen
sulphur
atom
within
phosphodiest
linkag
gener
phosphorothio
backbon
ps
confer
increas
bind
plasma
protein
resist
nucleas
activ
prolong
halflif
aso
addit
order
allow
highaffin
interact
target
mrna
splice
occur
rather
mediat
mrna
destruct
aso
support
ribonucleas
h
activ
sever
aso
fulfil
criteria
test
cell
ps
modif
second
gener
aso
lock
nucleic
acid
lna
ethylenebridg
nucleic
acid
ena
peptid
nucleic
acid
pna
tricyclodna
phosphorodiamid
morpholino
pmo
third
gener
aso
fig
promis
aso
first
test
clinic
trial
ome
consist
methyl
modif
posit
sugar
moieti
pmo
contain
ps
backbon
oligoribonucleotid
segment
aso
exhibit
high
nucleas
resist
reduc
immun
stimul
due
ps
backbon
less
toxic
howev
lower
affin
target
compar
modifi
aso
pmo
third
gener
aso
deoxyribos
moieti
substitut
morpholin
ring
charg
phosphodiest
intersubunit
linkag
replac
nonion
phosphorodiamid
linkag
nonribos
base
modif
render
pmo
immun
nucleas
activ
nonion
natur
minim
nuclear
uptak
numer
research
group
shown
success
restor
dystrophin
use
pmo
base
aso
dmd
anim
model
commonli
use
mdx
mous
harbour
spontan
nonsens
mutat
exon
result
earli
termin
codon
mild
moder
dmd
histopatholog
featur
contrari
human
model
gener
via
target
delet
exon
correspond
socal
hot
spot
exon
region
dmd
mutat
map
patient
mdx
mous
exon
remov
disrupt
dmd
read
frame
allow
mrna
induct
littl
shorter
dystrophin
product
simul
becker
phenotyp
intramuscular
inject
aso
administ
weekli
week
period
even
singl
dose
mdx
muscl
induc
dystrophin
synthesi
improv
function
treat
muscl
repeat
system
administr
aso
elev
dystrophin
normal
wild
type
level
gastrocnemiu
intercost
abdomin
muscl
quadricep
intramuscular
intraven
inject
pmo
mdx
mice
induc
bodywid
distribut
dystrophin
meaning
therapeut
level
compar
aso
studi
albeit
high
variabl
among
sampl
mous
model
exon
skip
predict
gener
becker
phenotyp
similar
human
system
deliveri
pmo
cocktail
mice
seven
time
weekli
interv
induc
wildtyp
dystrophin
express
muscl
treatment
could
theoret
appli
high
percentag
dmd
patient
multiexon
skip
perform
mutat
hot
spot
exon
achiev
system
inject
ten
pmo
restor
dystrophin
level
account
patient
harbour
delet
mutat
mdx
dystroph
phenotyp
less
sever
one
observ
human
mildli
impair
muscl
function
normal
lifespan
due
utrophin
compens
need
find
altern
anim
model
test
efficaci
pharmacodynam
safeti
drug
purpos
multi
exon
skip
exon
exon
use
pmo
cocktail
success
appli
golden
retriev
canin
dog
model
vitro
canin
x
link
muscular
dystrophi
model
cxmdj
vivo
amelior
patholog
phenotyp
without
trigger
seriou
side
effect
collabor
project
use
cxmdj
model
bred
facil
thoroughli
investig
system
efficaci
safeti
multiexon
skip
use
combin
pmo
cocktail
similar
approach
adopt
current
studi
assess
potenc
safeti
novel
ppmo
cocktail
fig
major
dmd
mutat
human
cluster
exon
socal
hot
spot
mutat
exon
repres
dmd
patient
popul
make
subgroup
attract
target
clinic
trial
use
singl
exon
skip
approach
first
experiment
clinic
trial
use
omep
base
drug
call
drisapersen
target
exon
develop
prosensa
glaxosmithklin
gsk
late
biomarin
preliminari
data
phase
clinic
trial
encourag
indic
dystrophin
build
dosedepend
manner
reach
healthi
muscl
two
random
placebocontrol
phase
clinic
trial
demonstr
improv
walk
test
children
treat
mgkgweek
drisapersen
administ
subcutan
period
week
effect
maintain
albeit
reduc
signific
week
treatment
howev
result
reproduc
phase
iii
placebocontrol
trial
follow
dystrophin
product
detect
western
blot
treat
patient
muscl
obtain
biopsi
although
increas
sarcolemm
dystrophin
myofib
observ
immunohistochemistri
advers
effect
skin
fragil
site
inject
proteinuria
presenc
alpha
microalbumin
urin
occur
becam
promin
dose
scale
mgkgweek
therefor
us
food
drug
administr
fda
declin
approv
basi
standard
effect
met
howev
intensifi
effort
overcom
toxic
problem
led
develop
optim
stereopur
aso
characterist
exampl
design
skip
exon
dmd
gene
yield
promis
vitro
mousebas
exon
skip
data
efficaci
safeti
current
assess
phase
clinic
trial
fda
recent
approv
eteplirsen
exondi
sarepta
therapeut
target
exon
dmd
patient
achiev
around
posit
dystroph
fiber
administ
intramuscularli
extensor
digitorum
brevi
dmd
patient
singleblind
placebocontrol
trial
therefor
eteplirsen
like
drisapersen
could
success
mediat
exon
skip
dystroph
patient
subsequ
eteplirsen
test
system
nonrandom
phase
iii
random
phase
ii
clinic
trial
show
skip
exon
variabl
natur
patient
substanti
increas
dystrophinposit
fiber
high
dose
cohort
group
longer
treat
cohort
group
minim
side
effect
function
assess
use
demonstr
decreas
rate
ambul
loss
eteplirsen
treat
patient
howev
elabor
assess
indic
variabl
exon
skip
effici
occur
among
patient
dystrophin
restor
non
homogen
differ
muscl
limit
drug
therapeut
potenti
current
success
exon
skip
therapi
determin
percentag
effici
exon
skip
result
express
level
restor
protein
two
paramet
alway
well
correl
may
account
observ
phenotyp
strongli
deviat
earlier
laboratori
find
exampl
eteplirsentr
patient
mgkg
dose
administ
weekli
week
result
mean
dystrophinposit
fibr
origin
clinic
trial
percentag
dystrophin
protein
patient
reevalu
fda
use
western
blot
techniqu
consid
reliabl
quantif
method
low
compar
untreat
control
furthermor
system
administr
eteplirsen
appear
increas
dystrophin
posit
fibr
phase
trial
latest
data
show
eteplirsen
may
restor
dystrophin
yield
similar
find
nonapprov
drisapersen
take
account
mild
dystrophinopathi
observ
patient
possess
dystrophin
make
assumpt
achiev
least
dmd
mrna
knock
essenti
amelior
dmd
phenotyp
wherea
dystrophin
may
enough
significantli
increas
surviv
sever
diseas
patient
percentag
target
mention
far
one
highlight
statist
obtain
eteplirsen
trial
furthermor
whether
elev
percentag
dystrophinposit
fibr
signific
deem
respons
amelior
clinic
perform
patient
measur
debat
especi
pool
statist
eteplirsen
case
approv
eteplirsen
non
unanim
controversi
spark
debat
among
fda
member
scientist
still
conclus
whether
eteplirsen
success
halt
diseas
progress
diagnos
dmd
patient
decis
hope
pave
way
elabor
robust
pmo
clinic
trial
design
recent
institut
conclud
phase
openlabel
studi
collabor
nippon
shinyaku
co
ltd
doseescal
clinic
trial
evalu
exon
skip
efficaci
pmo
could
target
dmd
patient
popul
pmo
demonstr
dosedepend
exon
skip
efficaci
success
dystrophin
express
minim
side
effect
recent
releas
data
nippon
shinyaku
indic
level
dystrophin
express
patient
particip
phase
iii
clinic
trial
averag
wellsurpass
efficaci
data
report
approv
drug
eteplirsen
sarepta
therapeut
recent
announc
plan
submit
new
drug
applic
obtain
acceler
approv
exon
target
pmo
base
drug
call
golodirsen
gener
promis
data
phase
iii
clinic
trial
efficaci
safeti
golodirsen
anoth
pmo
drug
call
casimersen
target
exon
dmd
gene
approxim
correspond
patient
popul
current
evalu
ongo
essenc
phase
iii
doubleblind
assess
new
era
aso
base
drug
lead
novel
treatment
regimen
succeed
deliv
dystrophin
restor
minim
advers
effect
bring
hope
patient
suffer
genet
neuromuscular
diseas
main
limit
pmo
therapeut
agent
dmd
underlin
numer
animalbas
studi
poor
cellular
uptak
permeabl
membran
barrier
rapid
clearanc
system
circul
inabl
cross
bloodbrain
barrier
variabl
dystrophin
express
distribut
variou
target
tissu
within
tissu
short
durat
exon
skip
effect
requir
repetit
administr
andor
high
dosag
drug
sever
mousebas
studi
conduct
aim
amelior
poor
pmo
uptak
system
administr
enhanc
intracellular
deliveri
littl
progress
made
far
fact
high
repeat
system
dose
pmo
necessari
achiev
upregul
dystrophin
skelet
muscl
anim
model
without
signific
effect
diaphragm
heart
observ
unexpect
consid
pmo
chemic
natur
origin
pmo
thought
molecul
net
electr
charg
thu
unabl
form
complex
deliveri
vector
fact
minim
offtarget
effect
render
suitabl
intramuscular
administr
unfortun
reduc
overal
abil
cross
cell
membran
thu
system
efficaci
base
research
data
recent
publish
group
pmo
may
neg
zeta
potenti
enabl
form
complex
pmo
uptak
occur
passiv
diffus
dystrophindefici
leaki
muscl
fiber
readili
intern
intramuscularli
administ
pmo
fact
eteplirsen
potenti
penetr
leaki
muscl
cell
exert
therapeut
effect
howev
treat
muscl
start
build
dystrophin
automat
becom
less
leaki
thu
less
penetr
prevent
addit
entri
pmo
hamper
homogen
dystrophin
build
notion
agreement
interpret
data
deriv
pmo
trial
use
mdx
mous
model
observ
cycl
muscl
regenerationdegener
taken
place
intermitt
pmo
system
high
dose
deliveri
scheme
fact
possibl
account
dystrophin
fluctuat
observ
among
treat
mice
inabl
deliv
dosag
protect
dystroph
muscl
eccentr
contractioninduc
damag
hand
pmo
almost
alway
success
endocytos
due
hydrophob
plasma
membran
trace
intern
pmo
escap
endosom
reach
target
therefor
deliveri
pmo
tissu
cultur
aid
use
endoport
convert
poli
cation
form
insid
acidifi
endosom
compart
render
endosom
membran
permeabl
coval
linkag
octaguanidinium
dendrim
scaffold
end
pmo
ring
lead
gener
modifi
morpholino
call
vivo
morpholino
vpmo
vpmo
test
mous
model
well
dystroph
dog
model
case
shown
optim
effici
splice
modul
skelet
dystrophin
product
effect
way
enhanc
pmo
penetr
cell
membran
conjug
short
cell
penetr
peptid
cpp
cpp
also
known
protein
transduct
domain
short
peptid
cation
amphipath
hydrophob
natur
abil
form
complex
cargo
molecul
success
transport
activ
biolog
conjug
insid
cell
experi
use
cpp
includ
tat
protein
drosophila
antennapedia
protein
oligoarginin
peptid
crosslink
enhanc
pmo
uptak
cell
intern
tat
protein
conjug
impair
possibl
due
strong
electrostat
interact
form
cellular
heparin
sulfat
endocytosi
third
alpha
helix
domain
antennapedia
also
known
penetratin
wide
use
maxim
effici
intern
fail
deliv
signific
amount
nucleu
moreov
enzym
degrad
throughout
deliveri
instabl
conjug
human
serum
factor
pose
hurdl
toward
use
system
deliveri
thu
limit
therapeut
potenti
enhanc
pmo
deliveri
cpp
subsequ
enrich
arginin
cation
amino
acid
could
potenti
facilit
deliveri
neutral
charg
pmo
cell
compart
conjug
pmo
penetratin
contain
six
arginin
residu
near
nterminu
bulki
sidechain
compos
hydrophob
amino
acid
gener
new
class
pmo
call
pmo
intern
peptid
pip
enhanc
cellular
uptak
capac
stabil
serum
proteolysi
insert
acid
residu
x
peptid
increas
correspond
cpp
serum
stabil
nuclear
deliveri
fail
prevent
intracellular
degrad
incorpor
acid
oligoarginin
peptid
prevent
potenti
endosom
entrap
thu
greatli
enhanc
metabol
stabil
wherea
insert
skeleton
increas
intracellular
stabil
origin
cpp
use
conjug
deriv
natur
occur
protein
alreadi
proven
excel
transloc
properti
understand
structur
activ
relationship
cpp
led
synthesi
cpp
base
predict
algorithm
therefor
exist
cpp
heterogen
natur
result
peptid
conjug
morpholino
ppmo
taken
vitro
prolifer
myoblast
termin
differenti
myotub
via
poorli
understood
process
call
gymnosi
requir
vehicl
transfect
reagent
deliveri
fact
argininerich
cpp
conjug
pmo
remark
enhanc
cellular
uptak
pmo
also
improv
pharmacophor
potenc
describ
detail
later
section
summari
vitro
anim
studi
undertaken
field
dmd
pleas
refer
tabl
intern
pmo
cell
occur
via
interchang
pathway
depend
upon
natur
cell
fig
cell
surfac
pmo
adsorpt
mediat
clathrin
caveolindepend
less
frequent
independ
endocyt
process
aid
cell
surfac
receptor
integrin
g
protein
coupl
receptor
receptor
tyrosin
kinas
tolllik
receptor
scaveng
receptor
aso
intern
cell
via
endocytosi
effect
deliv
nucleu
exert
splice
effect
cpp
conjug
implement
order
increas
cellular
uptak
pmo
poor
requir
larg
dosag
repeat
administr
reach
target
similarli
pmo
uptak
preval
theori
regard
ppmo
uptak
via
endocytosi
mainli
mediat
class
scaveng
receptor
subtyp
scara
interact
greatli
enhanc
propens
amphipath
ppmo
selfassembl
nanoparticl
furthermor
net
charg
ppmo
call
zeta
potenti
neg
measur
isoton
media
may
influenc
interact
individu
ppmo
plasma
membran
strengthen
notion
receptor
necessari
intern
ppmo
addit
penetratin
boost
abil
ppmo
penetr
cell
membran
differenti
neuron
cultur
addit
b
peptid
shown
facilit
heparin
sulphat
proteoglycan
bind
thu
enhanc
intern
ppmo
endosom
pathway
observ
readili
intern
myotub
rather
myoblast
possibl
due
higher
endosom
entrap
limit
avail
independ
leaki
membran
group
attribut
diminish
potenc
cardiac
cell
versu
skelet
muscl
cell
differ
endocyt
pathway
intern
rout
consider
hurdl
pmo
endocytosi
contribut
limit
system
therapeut
effect
endosom
entrap
peptid
contain
polyarginin
analogu
induc
leakag
endosom
aid
releas
conjug
pmo
cytosol
pmo
firstgener
ppmo
tat
penetratin
backbon
requir
high
concentr
compound
induc
effici
target
exon
skip
well
escap
endosom
entrap
addit
penetratin
pip
compound
allow
effici
splice
much
lower
dose
fact
inject
conjug
ppmo
tibiali
anterior
mdx
mous
result
effici
exon
skip
significantli
higher
dystrophin
rescu
compar
nake
pmo
pretreat
tibiali
anterior
muscl
mdx
mice
ppmo
allow
rescu
dystrophin
express
low
dosag
aav
administr
prevent
aav
genom
loss
potenti
microdystrophin
base
gene
therapi
repeat
intraperiton
administr
ppmo
doubl
utrophindystrophin
ko
mous
show
sever
phenotyp
mdx
mous
deem
appropri
model
test
therapeut
effect
pmo
restor
dystrophin
express
skelet
muscl
includ
diaphragm
prevent
onset
dystroph
phenotyp
howev
ppmo
administr
advanc
stage
diseas
fail
prevent
diseas
progress
although
significantli
delay
diseas
progress
appli
mice
earli
stage
diseas
evalu
seri
ppmo
compris
variabl
number
acid
x
b
residu
intraperiton
deliveri
mice
use
premrna
report
ascertain
ppmo
entri
cell
shown
b
conjug
peptid
effect
one
sustain
dystroph
protein
express
target
heart
diaphragm
quadricep
key
muscl
dmd
patient
independ
studi
bpmo
conjug
administ
intraven
inject
mdx
mice
confirm
high
efficaci
bpmo
dystrophin
correct
mdx
skelet
muscl
overt
hepat
renal
toxic
observ
direct
demonstr
cell
penetr
peptid
may
accentu
vivo
nucleic
acid
deliveri
came
group
one
year
later
author
describ
chimer
fusion
peptid
gener
conjug
musclespecif
heptapeptid
b
peptid
induc
effect
exon
skip
result
effici
restor
dystrophin
multipl
skelet
muscl
well
signific
increas
muscl
strength
mdx
mous
model
advantag
ppmo
pmo
induc
effici
system
target
specif
exon
skip
amelior
dmd
phenotyp
evid
pioneer
studi
mdx
mice
confirm
virtual
everi
studi
undertaken
sinc
gener
peptid
nucleic
acid
pmo
intern
peptid
pip
seri
contain
two
argininerich
domain
separ
central
short
hydrophob
core
design
order
improv
serum
stabil
drive
effici
exon
skip
varieti
target
tissu
increas
heart
dystrophin
product
inde
pmo
seri
capabl
restor
dystrophin
express
bodi
wide
follow
singl
intraven
inject
studi
seri
demonstr
amelior
dmd
patholog
phenotyp
exercis
mice
dystrophin
built
tissu
aid
restor
dgc
integr
proper
local
betadystroglycan
improv
muscl
power
improv
phenotyp
mice
dog
identif
candid
musclehom
peptid
subsequ
conjug
aso
may
improv
deliveri
target
tissu
maxim
therapeut
effect
dmd
patient
diaphragm
function
sever
compromis
lead
progress
declin
ventil
prematur
death
mdx
mous
model
diaphragm
exhibit
fibrot
pattern
loss
elast
increas
collagen
densiti
becom
best
muscl
studi
repres
histolog
chang
dystroph
phenotyp
anim
model
repetit
administr
rxr
conjug
x
aminohexano
acid
b
alanin
effect
restor
dystrophin
express
diaphragm
mdx
mice
treatment
appli
earli
neonat
stage
howev
effect
discontinu
longer
interv
final
inject
dystrophin
express
diaphragm
neonat
mdx
mice
increas
dosedepend
singl
intraperiton
inject
mgkg
rxr
peptidebas
ppmo
reach
level
compar
wildtyp
mice
system
administr
chimer
bmsppmo
mgkg
induc
diaphragmat
dystrophin
level
similar
gastrocnemiu
bicep
one
intraperiton
inject
dosag
mgkgweek
six
week
highli
restor
diaphragmat
level
dystrophin
amelior
sever
patholog
dystrophinutrophin
doubl
knockout
mous
studi
carri
use
reveal
singl
intraven
administr
mgkg
restor
diaphragmat
dystrophin
percentag
drop
lower
dosag
mgkg
administ
system
mdx
mice
seri
improv
dystrophin
diaphragmat
target
singl
dose
mgkg
bpmo
administ
intraperiton
markedli
restor
diaphragmat
dystrophin
wherea
dosag
deliv
intraven
also
elev
dystrophin
intercost
sternomastoid
muscl
mdx
mice
cardiomyopathi
unavoid
consequ
dmd
present
almost
patient
year
form
dilat
cardiomyopathi
account
mortal
dmd
patient
absenc
myocardi
dystrophin
lead
fibrosi
condit
aggrav
cardiac
workload
stimul
autonom
system
increas
heart
rate
compens
mechan
worsen
exist
ventricular
dysfunct
pmo
administr
fail
aid
cardiac
function
improv
anim
model
test
possibl
due
inabl
drug
enter
imperm
cardiomyocyt
membran
even
high
dose
pmo
mgkg
administ
intraven
biweekli
interv
one
year
mdx
mous
shown
littl
efficaci
upregul
dystrophin
protein
level
myocardium
improv
cardiac
output
stress
respons
effect
exon
skip
observ
cardiac
myoblast
obtain
mdx
mice
vitro
albeit
much
higher
dose
one
necessari
produc
effect
skelet
muscl
cell
low
level
skip
effici
cardiac
muscl
rang
upon
pmo
system
administr
observ
almost
everi
pmo
studi
publish
far
despit
achiev
higheffici
dystrophin
express
skelet
muscl
notabl
intracardiac
inject
nake
morpholino
oligo
age
mdx
mice
yield
low
exon
skip
percentag
avail
treatment
capabl
restor
dystrophin
protein
heart
dmd
patient
fact
pivot
signific
high
risk
failur
proper
cardiac
function
per
se
remain
one
main
culprit
prematur
mortal
dmd
patient
also
aggrav
cardiac
diseas
progress
occur
result
increas
work
load
origin
amelior
skelet
muscl
function
enhanc
locomotor
activ
use
current
treatment
regim
need
effici
target
infram
exon
skip
particularli
cardiac
muscl
led
explor
divers
structur
ppmo
restor
dystrophin
skelet
muscl
diaphragm
mdx
mous
sever
affect
dystrophinutrophin
doubl
knock
mous
absenc
cardiac
dystrophin
express
restor
cardiac
function
wild
type
level
suggest
target
respiratori
muscl
may
prevent
cardiomyopathi
dmd
patient
howev
intraven
administr
mgkg
dose
bpmo
deliv
intraven
intraperiton
restor
dystrophin
level
respiratori
muscl
fail
improv
cardiac
function
mdx
mice
argininerich
ppmo
backbon
rxrrbr
target
exon
mdx
mous
name
success
restor
dystrophin
almost
normal
level
time
protect
heart
muscl
damag
dobutamin
stress
challeng
system
administr
argininerich
ppmo
induc
exon
skip
effici
rescu
cardiac
dystrophin
mdx
mous
inhibit
onset
progress
cardiomyopathi
dystrophin
express
detect
heart
mdx
mice
three
week
administr
singl
intraven
inject
rxr
backbon
effect
rxrrbr
peptid
found
dosag
mgkg
biweekli
year
rather
higher
treatment
regim
mgkg
monthli
restor
dystrophin
cardiac
muscl
indic
treatment
space
equal
import
dosag
regim
singl
intraven
inject
conjug
peptid
induc
dystrophin
express
heart
mdx
adult
mice
attribut
increas
nuclear
deliveri
cardiomyocyt
gener
seri
pmo
alter
peptid
hydrophob
core
sequenc
carri
order
promot
homogen
dystrophin
restor
particularli
effici
target
cardiac
muscl
fact
invers
hydrophob
core
yield
cardiac
dystrophin
recoveri
score
high
mdx
mous
model
wherea
specif
arrang
hydrophob
residu
within
core
alter
efficaci
construct
exon
skip
group
shown
administr
scrambl
peptid
core
may
restor
dystrophin
protein
level
heart
mdx
mice
previous
subject
forc
exercis
regimen
induc
chang
mimic
dmd
cardiac
phenotyp
moreov
mice
exhibit
lower
level
fibrosi
inflammatori
oxid
marker
well
sign
indic
cardiomyopathi
progress
cxmdj
dog
model
monthli
intraven
inject
b
peptid
conjug
pmo
cocktail
singl
intracoronari
intraven
inject
success
induc
multi
exon
skip
rescu
dystrophin
express
part
cardiac
muscl
assess
western
blot
dystrophin
protein
express
amelior
vacuol
degener
purkinj
fibr
increas
qr
ratio
treat
dog
term
neurodegen
diseas
encompass
rang
progress
disord
character
gradual
degener
structur
function
nervou
system
repres
exampl
parkinson
diseas
alzheim
diseas
huntington
diseas
hd
amyotroph
later
sclerosi
al
spinal
muscular
atrophi
sma
spinocerebellar
ataxia
divers
rang
pathophysiolog
memori
cognit
function
might
gradual
compromis
mobil
speech
unaffect
opposit
eventu
function
may
affect
risk
factor
diseas
sever
may
correl
advanc
age
eg
alzheim
genet
predisposit
eg
hd
eg
parkinson
earli
onset
alzheim
primari
caus
neurodegen
diseas
yet
identifi
percentag
age
popul
rapidli
expand
worldwid
global
effort
find
new
cure
neurodegen
condit
link
chang
found
age
brain
intensifi
cpp
show
improv
system
deliveri
cellular
uptak
due
proven
transmembran
transport
capac
list
promis
agent
treatment
central
nervou
system
diseas
cn
assum
otherwis
imperm
bloodbrain
barrier
bbb
neg
charg
membran
form
endotheli
cell
may
demonstr
increas
affin
small
size
cation
amphipath
cpp
especi
system
inflamm
present
individu
abnorm
neurolog
condit
case
cpp
arginin
core
high
charg
densiti
gener
may
enhanc
bbb
influx
rate
cpp
cross
bbb
use
differ
transport
mechan
adsorptivemedi
transcytosi
strong
electrostat
interact
gener
neg
charg
phospholipid
may
aid
transloc
cpp
across
hydrophob
core
membran
exampl
mechan
employ
order
deliv
antiapoptot
protein
bcell
lymphomaextra
larg
bclxl
fusion
protein
tat
murin
brain
cure
ischaem
injuri
receptormedi
transcytosi
interact
cpp
transport
local
endotheli
cell
surfac
lowdens
lipoprotein
receptor
ldlr
lowdens
lipoprotein
receptorrel
protein
scaveng
receptor
class
type
srai
class
b
type
srbi
allow
cpp
passag
across
bbb
ppmo
may
effect
cross
bbb
reach
target
cn
administ
via
intrathec
inject
howev
invas
strategi
apart
caus
discomfort
patient
also
multipl
sideeffect
ppmo
manag
reach
cn
vascular
barrier
may
act
benefici
limit
escap
toward
peripheri
avoid
rapid
loss
drug
peripher
metabol
howev
numer
risk
factor
associ
intrathec
administr
infect
spinal
headach
neurolog
injuri
prompt
research
explor
intraven
administr
rout
anim
model
arginin
rich
cppconjug
pmo
effici
deliv
cerebellum
purkinj
cell
administ
via
tail
vein
mice
rais
hope
system
administr
ppmo
could
becom
conveni
rout
effect
target
cn
futur
system
deliveri
tricycl
dna
conform
constrain
oligonucleotid
analog
result
dystrophin
restor
brain
mdx
mice
although
cellular
intern
mechan
tricycl
dna
thu
mode
endotheli
barrier
cross
clarifi
author
sma
autosom
recess
diseas
caus
progress
loss
spinal
motor
neuron
lead
muscl
atrophi
motor
impair
sever
type
manifest
prematur
death
caus
homozyg
delet
mutat
surviv
motor
neuron
gene
wherea
phenotyp
variat
attribut
number
copi
centromer
homolog
call
surviv
motor
neuron
gene
transcript
lack
exon
interfer
smn
abil
oligomer
result
protein
product
rapidli
degrad
therefor
may
partial
compens
lack
inclus
exon
target
splice
regulatori
element
success
increas
fulllength
product
vitro
vivo
becom
promin
aso
therapybas
approach
sma
aso
chemistri
administ
intracerebroventricular
bolu
inject
success
taken
neuron
glial
cell
cn
sma
model
mous
induc
exon
inclus
improv
function
surviv
diseas
mice
nusinersen
isi
modifi
ps
aso
origin
develop
market
biogen
recent
approv
fda
drug
treatment
sma
nusinersen
intrathec
administr
result
signific
improv
motor
mileston
prolong
lifespan
sma
patient
minim
advers
effect
improv
system
deliveri
minim
side
effect
result
repeat
intrathec
inject
ppmo
trial
conduct
system
intraven
deliveri
pmo
increas
brain
spinal
cord
express
rescu
diseas
phenotyp
taiwanes
sever
sma
mous
model
recent
research
demonstr
deriv
apo
peptid
capabl
success
induc
premrna
exon
inclus
mous
model
spinal
muscular
atrophi
amelior
phenotyp
diseas
mice
sma
like
dmd
ppmo
treatment
focus
increas
product
function
protein
neurodegen
ppmo
clinic
trial
main
scope
reduc
aberr
mrna
transcript
hd
expans
cag
sequenc
insid
huntingtin
gene
result
elong
glutamin
stretch
near
amino
terminu
protein
product
toxic
lead
neuron
loss
mainli
striatum
cortex
affect
individu
suffer
progress
cognit
motor
impair
succumb
year
clinic
onset
aso
technolog
select
silenc
mous
huntingtin
identifi
exon
intron
singl
nucleotid
polymorph
site
vitro
vivo
pmo
design
target
cag
repeat
expans
administ
via
intracerebroventricular
inject
significantli
decreas
huntingtin
protein
express
reduc
neurotox
transgen
hd
mous
model
modul
epigenet
regul
call
repressor
silenc
transcript
factor
aso
exon
skip
striatal
cell
model
hd
rescu
transcript
neuron
gene
prove
exon
skip
may
prove
benefici
hd
clinic
trial
futur
chemistrybas
drug
ionishttrx
deliv
via
intrathec
inject
earli
stage
hd
patient
achiev
dosedepend
reduct
mutant
huntingtin
advers
effect
al
degener
upper
lower
motor
neuron
lead
progress
irrevers
paralysi
ultim
death
affect
individu
mutat
cuzn
superoxid
dismutas
gene
link
sporad
famili
al
thu
gene
one
main
target
al
clinic
trial
intrathec
deliveri
aso
isi
decreas
mrna
spinal
cord
recruit
al
patient
phase
random
control
trial
demonstr
excel
safeti
profil
albeit
concern
regard
toxic
remain
anoth
aso
compound
target
investig
placebocontrol
phase
iii
trial
order
establish
dosag
address
safeti
issu
current
phase
iii
clinic
trial
use
morpholino
oligom
silenc
diseas
onset
reduc
microgliosi
increas
motor
neuron
surviv
mous
model
al
furthermor
target
degrad
hexamer
expans
contain
rna
foci
gene
use
aso
reduc
accumul
expand
foci
dipeptid
repeat
protein
without
affect
overal
level
mrna
patient
cell
evid
sinc
pmo
therapeut
base
strategi
alreadi
success
applic
mani
neurodegen
diseas
potent
ppmo
may
hold
tremend
therapeut
potenti
field
well
aso
chemistri
target
exon
skip
ppmo
revolutionari
treatment
futur
could
becom
applic
major
dmd
patient
use
alon
combin
alreadi
approv
treatment
regim
exon
skip
may
aid
restor
partial
function
dystrophin
human
tissu
significantli
impact
qualiti
durat
life
dystroph
patient
recent
sarepta
therapeut
announc
initi
phase
iiia
clinic
trial
novel
ppmo
target
dmd
patient
amen
exon
skip
preclin
studi
use
five
ppmo
drug
candid
target
exon
dmd
also
part
sarepta
pipelin
current
main
limit
conduct
futur
clinic
trial
ppmo
base
drug
toxic
well
understood
toxic
may
depend
follow
factor
speci
durat
treatment
frequenc
system
administr
dosag
exon
chosen
skip
peptid
cation
natur
toxic
might
aris
due
immunogen
mechan
complement
activ
firstgener
argininerich
peptid
found
immunogen
pmo
furthermor
cellmedi
humor
respons
due
repetit
ppmo
treatment
serum
circul
antibodi
direct
newli
synthes
dystrophin
list
potenti
caus
toxic
mild
manifest
drug
toxic
low
dose
system
administr
rat
includ
lethargi
weight
loss
higher
dose
elev
creatinin
bun
record
similarli
ppmo
target
human
dystrophin
exon
found
well
toler
low
dose
howev
ongo
prolong
intraven
administr
caus
proxim
tubular
degener
kidney
cynomolgu
monkey
system
administr
pmo
monkey
caus
tubular
injuri
basophil
granul
tubular
vacuol
examin
kidney
deem
dosedepend
revers
upon
discontinu
treatment
preclin
trial
use
arginin
rich
ppmo
conduct
sarepta
termin
due
toxic
side
effect
could
partli
attribut
high
dosag
use
novel
biomark
acut
kidney
injuri
neutrophil
gelatinaseassoci
lipocalinar
ngal
highli
specif
sensit
inexpens
greatli
facilit
monitor
efficaci
experiment
treatment
anim
model
fact
latest
gener
pip
peptid
seri
purpos
design
contain
reduc
number
arginin
residu
compar
seri
shown
dramat
improv
toxic
profil
whilst
maintain
compound
splice
potenc
render
therapeut
index
favour
clinic
develop
work
novel
ppmo
seri
carri
group
collabor
new
spin
compani
call
pepgen
result
novel
seri
ppmo
compound
call
dpep
favour
toxic
profil
well
suit
futur
clinic
trial
howev
still
remain
challeng
estim
side
effect
longterm
administr
ppmo
human
prior
fulli
understand
pathophysiolog
toxic
dosag
treatment
regim
also
pivot
import
obtain
maxim
dystrophin
express
imped
develop
sever
offtarget
effect
offtarget
effect
aris
hybridizationmedi
mechan
issu
first
gener
aso
due
limit
abil
penetr
cellular
membran
unfortun
ppmo
conjug
maxim
target
deliveri
also
facilit
penetr
organ
liver
rais
concern
toxic
side
effect
use
lower
dose
space
system
inject
longer
interv
ppmo
administr
might
minim
side
effect
potenti
make
treatment
costeffect
friendlier
patient
exampl
care
select
pmo
dose
regim
mice
allow
signific
improv
dgc
express
complex
minim
histopatholog
featur
dmd
howev
group
show
intermitt
inject
pmo
irrespect
dosag
could
prevent
degenerationregener
cycl
treatment
lead
muscl
damag
uneven
distribut
dystrophin
among
tissu
occur
case
eteplirsen
clinic
trial
therefor
prior
appli
ppmo
treatment
regim
dmd
patient
vivo
efficaci
ppmo
prevent
degenerationregener
must
care
calcul
time
exon
skip
treatment
equal
import
dosag
regim
treatment
appli
onset
diseas
prior
manifest
sever
phenotyp
chanc
slow
progress
maxim
alreadi
demonstr
mdx
mous
model
inde
delay
onset
treatment
eteplirsen
clinic
trial
fail
prevent
loss
ambul
establish
destabil
interact
satellit
cell
surround
environ
lead
exacerb
inflamm
fibrosi
complic
dmd
pathogenesi
understand
even
success
exon
skip
restor
dystrophin
express
sever
muscl
group
advanc
diseas
patient
newli
produc
dystrophin
abl
revers
patholog
process
alreadi
taken
place
due
destabil
dgc
complex
importantli
benefici
effect
genet
correct
dmd
defect
may
obscur
hamper
qualiti
muscl
advanc
fibrosi
exhaust
satellit
cell
pool
reduc
myofib
product
common
patholog
chang
observ
dystroph
muscl
therefor
surpris
ppmo
treatment
effect
advanc
diseas
patient
prolong
absenc
dystrophin
led
advanc
fibrofatti
degener
condit
creat
ideal
environ
dystrophin
restor
viciou
cycl
broken
combin
exist
therapi
ppmo
skip
appli
improv
qualiti
life
patient
system
deliveri
aso
majorli
improv
peptid
conjug
howev
tissu
like
heart
diaphragm
demonstr
high
effici
exon
skip
sustain
express
dystrophin
remain
challeng
although
studi
attribut
imperm
natur
cardiomyocyt
cardiac
level
ppmo
inject
mdx
mice
measur
elisa
compar
tissu
hint
poor
efficaci
ppmo
heart
may
necessarili
connect
poor
deliveri
mode
subcellular
uptak
major
drawback
order
optim
deliveri
tissu
lack
predict
ppmo
effici
secondari
structur
abil
pmo
success
induc
exon
skip
dmd
gene
transcript
depend
mani
factor
length
affin
bind
proxim
acceptor
splice
site
abil
block
exon
splice
enhanc
interfer
serinearginin
protein
bind
silico
prescreen
model
base
measur
paramet
bind
energet
aso
rna
distanc
target
site
splice
acceptor
site
may
give
accur
predict
pmo
exonskip
efficaci
anim
ppmo
studi
undertaken
far
promis
howev
major
care
taken
prior
translat
find
human
studi
fact
lack
understand
optim
ppmo
exon
skip
effici
via
structur
modif
hinder
path
discoveri
potent
ppmo
cocktail
current
exon
skip
therapi
target
one
exon
thu
applic
limit
number
individu
harbour
specif
mutat
ongo
clinic
trial
pmo
target
exon
conduct
sarepta
pharmaceut
even
none
mention
regim
address
patient
harbour
mutat
exon
exon
mutat
hotspot
dmd
gene
account
patient
therefor
multiexon
skip
treatment
regim
cover
two
hot
spot
region
approv
treatment
may
applic
almost
half
dmd
commun
time
drug
target
multiexon
skip
exon
would
render
patient
asymptomat
circumv
unknown
truncat
protein
stabilityfunct
factor
issu
type
dmd
patient
exhibit
mild
characterist
diseas
detect
truncat
dmd
mrna
around
mutat
hot
spot
reveal
presenc
among
other
lowli
express
exon
multiexon
skip
product
dmd
mrna
ideal
induct
target
exon
skip
therapi
studi
myotub
transdifferenti
dmd
patient
fibroblast
cell
recent
publish
demonstr
pmo
oligom
could
produc
dosedepend
exon
skip
indic
therapeut
effect
could
effect
achiev
use
ppmo
near
futur
futur
goal
develop
genet
strategi
appli
individu
dmd
order
achiev
effici
multipl
exon
skip
could
potenti
applic
patient
need
administ
ppmo
cocktail
rather
singl
drug
requir
synthesi
screen
differ
oligom
well
valid
safeti
efficaci
throughout
clinic
trial
approach
inevit
increas
cost
treatment
well
risk
potenti
immunolog
complic
aris
combin
differ
chemic
substanc
final
keep
mind
rather
conserv
approach
requir
review
valid
drug
efficaci
data
solidli
base
dystrophin
quantif
clear
doserespons
effect
dmd
phenotyp
posit
correl
amount
dystrophin
protein
quantifi
muscl
biopsi
establish
yet
vitro
exon
skip
efficaci
quantif
dystrophin
express
mainli
perform
use
primari
cell
model
line
hard
maintain
altern
screen
system
current
investig
object
posttherapeut
evalu
muscl
function
recoveri
pend
due
inadequaci
assess
muscl
function
clinic
situat
besid
muscl
biopsi
highli
invas
techniqu
particularli
difficult
excus
necess
intensifi
frequenc
patient
involv
children
physic
evalu
patient
motor
activ
pivot
import
howev
done
patient
visit
hospit
fail
monitor
progress
daili
task
data
obtain
function
measur
debat
previou
clinic
trial
lead
exclus
mani
patient
identif
novel
pharmacolog
biomark
hope
allow
patientfriendli
assess
approach
ppmo
therapeut
effect
exampl
biomark
mirna
releas
bloodstream
dmd
patient
result
fiber
damag
detect
serum
sampl
fold
chang
elev
level
coincid
sever
diseas
whilst
reduct
associ
posit
respons
exon
skip
treatment
dystrophin
restor
step
need
take
order
facilit
translat
novel
ppmo
treatment
clinic
clear
multidisciplinari
approach
need
ensur
safeti
futur
clinic
trial
firstli
note
although
great
number
dmd
anim
model
current
avail
none
model
perfectli
assimil
human
phenotyp
pose
signific
hurdl
drug
test
widespread
use
mdx
murin
model
exhibit
patholog
characterist
diseas
mild
phenotyp
normal
life
span
switch
larger
mammal
accur
evalu
key
clinic
mileston
pose
ethic
financi
issu
prohibit
factor
maintain
coloni
mani
research
facil
therefor
prioriti
establish
appropri
preclin
model
diseas
human
induc
pluripot
stem
cell
ip
success
program
produc
skelet
muscl
construct
express
characterist
marker
matur
myod
myosin
heavi
chain
ip
cell
deriv
dystroph
patient
use
order
creat
skelet
muscl
platform
accur
portray
cellular
hallmark
diseas
multipl
studi
conduct
use
patient
deriv
ip
cell
order
evalu
approach
dystrophin
restor
exon
skip
exon
knock
thu
develop
evalu
novel
drug
futur
success
engraft
correct
patientderiv
ip
cell
may
turn
safe
ex
vivo
appli
gene
therapi
variabl
age
sever
clinic
symptom
amongst
speci
common
factor
exist
dmd
anim
model
also
human
patient
reason
need
increas
number
clinic
trial
human
order
establish
proof
concept
emphasi
given
small
clinic
trial
adequ
prepar
necessari
start
registri
follow
document
contain
detail
natur
histori
patient
pivot
order
accur
monitor
benefici
potenti
side
effect
drug
test
sinc
onset
clinic
cours
dmd
well
describ
emphasi
clinician
current
given
toward
accur
monitor
diseas
mileston
progress
abil
walk
stand
climb
stair
therefor
test
time
function
test
repres
current
clinic
endpoint
biochem
endpoint
correl
abil
gene
therapi
treatment
restor
dystrophin
reduc
fibrosi
correl
dystrophin
product
improv
muscl
strength
physic
activ
especi
younger
patient
closest
monitor
pair
biochem
clinic
end
point
essenti
order
evalu
drug
efficaci
earli
clinic
trial
improv
exist
clinic
endpoint
achiev
use
novel
technolog
eg
sophist
devic
effect
monitor
evalu
physic
activ
patient
natur
environ
novel
therapeut
strategi
use
antisens
oligonucleotid
tremend
alter
clinic
outcom
life
expect
prognosi
patient
field
neuromuscular
diseas
last
decad
two
aso
base
drug
obtain
approv
fda
treatment
dmd
sma
respect
pave
way
novel
discoveri
molecular
therapi
ppmo
compound
show
increas
efficaci
splice
correct
agent
lower
dose
nake
aso
effect
restor
dystrophin
bodi
wide
distribut
skelet
tissu
administ
system
unfortun
attempt
util
ppmo
treatment
neurodegen
diseas
far
plagu
lack
deliveri
cn
plu
toxic
ongo
research
aid
clarif
pharmacodynam
mode
action
ppmo
unravel
mechan
benefici
action
hope
enabl
synthesi
novel
ppmo
drug
minim
offtarget
effect
maxim
effici
uptak
skelet
respiratori
cardiac
tissu
ultim
cn
bring
hope
better
qualiti
life
patient
